TVM Capital Healthcare Announces $35 Million Investment in Boston Oncology Arabia TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a $35 million investment in Boston…
ImmunoPrecise Antibodies Ltd. (IPA), an AI-driven biotherapeutic research and technology company, announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI. This partnership aims to leverage BioStrand’s patented LENSai Foundation…
PQE Group, a prominent consultancy in the Life Science sector, has announced the launch of its new Regulated Artificial Intelligence & Data Analytics division. This development follows the integration of…
As the world’s largest pure-play consumer health company by revenue, Kenvue has released its first-ever Healthy Lives Mission Report, highlighting the company’s efforts to enhance the well-being of both people…
argenx Receives FDA Approval for VYVGART® Hytrulo with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy Today, Halozyme announced that the U.S. Food and Drug Administration (FDA) has approved argenx’s VYVGART® Hytrulo…
Bayer AG and Charité – Universitätsmedizin Berlin Unveil Plans for Berlin Center Advancing Gene and Cell Therapies Today, Bayer AG and Charité – Universitätsmedizin Berlin announced their joint initiative to…
Takeda has announced that the European Commission (EC) has approved FRUZAQLA (fruquintinib) as a monotherapy for adult patients with metastatic colorectal cancer (mCRC) who have previously been treated with standard…
Takeda today announced positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune…
Sanofi is set to present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), occurring from June 22-26, 2024, in…
Today, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI® (adagrasib) in combination with cetuximab. This targeted treatment is for adult…
Bristol Myers Squibb announced today that the European Medicines Agency (EMA) has validated its application to introduce a new subcutaneous administration route for Opdivo® (nivolumab). This includes a new pharmaceutical…
Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed…